Differentiation Of Acute Rejection From Infection In Rat

心脏移植后急性排斥反应和感染仍然是心脏移植后发病率和死亡率的主要来源，占报告死亡人数的近50%。通常很难在临床上区分排斥反应和感染，因为它们都是炎症过程，具有相似的非特异性症状。然而，这种差异对于确定治疗方案是必不可少的。在移植患者中找出安全而简明的早期区分排斥反应和感染的实验室方法将大大改善结果。我们已经建立了一种ACUC方案，使我们能够研究外周血单个核细胞(PBMC)的基因芯片分析是否能够可靠地区分移植大鼠的急性心脏排斥反应和感染。ACUC协议还允许我们进行必要的试点研究，以支持主要协议。到目前为止，我们已经建立了成功进行和维持大鼠移植模型所必需的外科技术。我们已经在这个模型中建立了一个剂量的环孢素(CsA)，在给药期间可以可靠地抑制排斥反应，但在停止使用时将允许出现3级排斥反应。我们还确定了在接受CsA的移植大鼠中，适当的支气管内大肠杆菌接种足以引起肺炎和全身炎症反应，而不会立即致死。此外，我们还利用基因芯片技术研究了术后炎症变化的时间进程，以确定获取移植心脏的最佳时机(即手术炎症变化导致的基因芯片信号消失的时间)。我们即将完成主要研究方案。我们的主要方案结合了两个成熟的大鼠模型，第一个是异位心脏移植模型，第二个是大肠杆菌肺部感染模型。所有大鼠在第0天接受心脏移植，同时每日皮下注射CsA(10 mg/kg)以抑制排斥反应。移植后，动物在第6天随机停用CsA，以启动排斥反应，或继续进行，以进一步抑制排斥反应。停用环孢素A后，动物在第13天再次随机接受支气管内接种大肠杆菌或生理盐水接种。因此，正在研究四组：无感染的排斥反应(即接受CsA)、无感染的排斥反应(即接受CsA)、无感染的排斥反应(即未接受CsA)和有感染的排斥反应(即未接受CsA)。第14天，处死所有动物，取出血液和心脏进行基因芯片分析。其他可能使用的分析工具包括：RT-PCR、蛋白质印迹、原位杂交、蛋白质组学、免疫组织化学和组织病理学。此外，动物的肺、脾、肝和胸腺正在初步研究中获得，并为未来的潜在分析而保存。在上一次ACUC报告期间，73只动物被用于这一方案。

Acute cardiac allograft rejection and infection remain significant sources of morbidity and mortality after heart transplantation, accounting for nearly 50% of reported deaths. It is often difficult to clinically distinguish between rejection and infection because they are both inflammatory processes with similar, nonspecific symptoms. However, this differential is essential for determining therapy. Identifying laboratory methods that will permit safe and concise early differentiation between rejection and infection in the transplant patient will improve outcome substantially. We have established an ACUC protocol that allows us to study whether gene microarray analysis of peripheral blood mononuclear cells (PBMC) will reliably differentiate acute heart rejection from infection in the transplanted rat. The ACUC protocol also allows us to do pilot studies necessary to support the main protocol. To date, we have established the surgical techniques necessary to successfully perform and maintain the rat transplant model. We have established a dose of cyclosporin (CSA) in this model that reliably suppresses rejection during its administration, but will permit the emergence of Grade 3 rejection upon its discontinuation. We have also determined the appropriate inocula of intra-bronchial E. coli bacteria that is sufficient to cause a pneumonia and a systemic inflammatory response without being immediately lethal in transplanted rats receiving CSA. In addition, we have used gene microarry technology to study the time course of post surgical inflammatory changes in order to determine the most opportune time to harvest the transplanted hearts (i.e. when gene microarry signatures due to surgical inflammatory changes are dissapating). We are nearing completion of the main study protocol. Our main protocol combines two well-established rat models, the first is a heterotopic heart transplantation model and the second is an E. coli pulmonary infection model. All rats undergo heart transplantation on day 0 in conjunction with daily CSA (10 mg/kg subcutaneous) to suppress rejection. After transplant, animals are randomized at day 6 to have CSA discontinued, in order to initiate rejection, or continued, in order to further suppress rejection. After discontinuing CSA the animals are again randomized on day 13 to receive intrabronchial E. coli inoculation or saline inoculation. Consequently, four groups are being studied: No rejection (i.e. receiving CSA) without infection, no rejection (i.e. receiving CSA) with infection, rejection (i.e. not receiving CSA) without infection, and rejection (i.e. not receiving CSA) with infection. On day 14, all animals are sacrificed and the blood and heart removed for gene microarray analysis. Other analytic tools that may be employed include: RT-PCR, western blot, in-situ hybridization, proteomics, immunohistochemistry, and histopathology. In addition, the animals' lungs, spleen, liver, and thymus are being procured in the primary study and preserved for potential future analysis. Over the last ACUC reporting period, 73 animals have been used for this protocol.